Artisan Partners Limited Partnership Buys Shares of 460,802 LivaNova PLC (NASDAQ:LIVN)

Artisan Partners Limited Partnership purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 460,802 shares of the company’s stock, valued at approximately $21,340,000. Artisan Partners Limited Partnership owned 0.85% of LivaNova as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of LIVN. Point72 Asset Management L.P. boosted its holdings in LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after acquiring an additional 806,374 shares during the period. Vanguard Group Inc. boosted its stake in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after purchasing an additional 265,291 shares during the period. Raymond James Financial Inc. acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $9,645,000. Point72 DIFC Ltd increased its stake in LivaNova by 75,799.6% during the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after buying an additional 181,161 shares during the period. Finally, Ruffer LLP purchased a new position in LivaNova in the 4th quarter valued at approximately $7,982,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

Shares of LivaNova stock opened at $39.13 on Friday. The firm has a market capitalization of $2.13 billion, a P/E ratio of 93.17 and a beta of 1.10. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52 week low of $36.85 and a 52 week high of $64.48. The firm’s 50 day moving average is $44.51 and its two-hundred day moving average is $48.47.

Analyst Upgrades and Downgrades

LIVN has been the topic of several analyst reports. Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Mizuho decreased their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Barclays reduced their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Finally, Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.